IBRX Stock Climbs As Chairman Backs PDS Biotechnology PIPE

ImmunityBio Inc. jumps as positive clinical trial progress drives bullish sentiment, with stocks have been trading up by 10.61 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Market focus is on ImmunityBio’s ecosystem after its Executive Chairman backed a PIPE financing in PDS Biotechnology.
The company says its fundamentals are not changing around this announcement.
Patrick Soon‑Shiong is joining PDS Biotechnology’s board, expanding his oncology reach.
Traders see possible future collaboration between the two cancer platforms, but no clear near‑term financial shift yet.

Live Update At 12:32:02 EDT: On Friday, October 02, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 10.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

IBRX has been grinding higher on the chart. Over the past few weeks, ImmunityBio stock has pushed from the mid‑$7s to above $10, a strong percentage move that always catches momentum traders’ attention. The latest close around $10.27 shows dip buyers stepping in on each pullback.

On the daily chart, IBRX has strung together higher lows from 2026/09/11 near $7.91 to 2026/10/02 above $10. That’s a clear uptrend. The 5‑minute tape today shows a steady morning ramp from the $9.80–$10 area into the low $10s, then tight consolidation between roughly $10.25 and $10.50. That intraday action looks like strong hands holding, not a blow‑off top.

More Breaking News

Fundamentally, ImmunityBio is still a high‑burn clinical‑stage biotech. Revenue over the last period was only about $113.29M, but the company logged a net loss of roughly $230.38M for the quarter ending 2026/06/30. Margins are deeply negative, and EBITDA sat near -$194.74M. The flip side is balance‑sheet liquidity: IBRX reported a current ratio of 5.7 and quick ratio of 5.4, with about $357.37M in cash and short‑term investments. For traders, that mix screams “story stock” driven by catalysts and sentiment, not earnings power yet.

Why Traders Are Watching IBRX Now

Traders are zeroed in on IBRX this week because of a strategic move by its key leader, not because of a new trial result or partnership headline. ImmunityBio said its fundamentals are not changing here, but Executive Chairman and founder Patrick Soon‑Shiong is leading a PIPE financing into PDS Biotechnology and stepping onto PDSB’s board. That sounds subtle, but in biotech, these ecosystem moves can matter over time.

For ImmunityBio, the message is that Soon‑Shiong is still aggressively building out his oncology portfolio. IBRX already sits at the center of that vision. By backing PDS Biotechnology and gaining board‑level influence, he’s effectively widening the network around ImmunityBio’s platforms. Traders reading between the lines see optionality: potential trial combinations, data‑sharing, or co‑development paths that could tie IBRX and PDS Biotechnology closer together down the road.

At the same time, ImmunityBio made it clear that nothing in this announcement changes its own financial profile. The company still has heavy operating cash outflows — operating cash flow in the last reported quarter was about -$66.49M, with free cash flow near -$70.03M. Total liabilities are around $1.67B, and stockholders’ equity is negative, which is common in high‑burn biotechs but still a red flag for longer‑term valuation.

So why is IBRX holding near recent highs? Because traders care more about the story than the spreadsheet right now. The chart is trending, volume has been flowing in, and this PIPE news feeds a narrative that Soon‑Shiong is playing offense across oncology. For active traders, that combination of technical strength and strategic buzz keeps ImmunityBio squarely on the watchlist.

Conclusion

For short‑term and swing traders, IBRX is a classic speculative biotech play: strong recent price action, ugly traditional metrics, and a powerful narrative driver in Patrick Soon‑Shiong. ImmunityBio’s latest news about the PDS Biotechnology PIPE and his new board role does not rewrite the company’s balance sheet or income statement. The fundamentals — steep losses, high cash burn, and a reliance on future clinical wins — remain the same.

What does change is the perception of ImmunityBio’s reach. The more Soon‑Shiong connects IBRX with other oncology platforms like PDS Biotechnology, the more traders see a larger ecosystem forming around ImmunityBio. That can support sentiment on green days, but it also means any stumble in the broader portfolio might weigh on IBRX in the future.

As always, disciplined execution matters more than the story. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” The stock has run hard from sub‑$8 levels to above $10, and that move will not be straight up forever. Traders watching ImmunityBio need clear plans for entries, exits, and risk. Tim Sykes says it best: “Patterns repeat, but only prepared traders profit from them.” For IBRX, the pattern right now is momentum backed by a busy chairman — and traders should treat it as an educational case study in how story, structure, and price action collide.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!